You Position: Home > Paper

Research progress of high-dose-rate brachytherapy for primary non-small cell lung cancer

( views:5, downloads:0 )
Author:
No author available
Journal Title:
International Journal of Radiation Medicine and Nuclear Medicine
Issue:
6
DOI:
10.3760/cma.j.cn121381-202302017-00427
Key Word:
近距离放射疗法;癌;非小细胞肺;高剂量率;安全性

Abstract: Non-small-cell lung cancer(NSCLC)is the most common histopathological type of lung cancer,accounting for about 85%-90%of lung cancer.At present,surgical resection is the first choice for NSCLC,but there are still some patients who are not suitable for surgery or refuse surgery because of various reasons.Therefore,the local treatment for this kind of NSCLC patients has become the research hotspot.High-dose-rate brachytherapy(HDR-BT)is a new modality for the treatment of NSCLC,has good efficacy in the treatment of NSCLC.By analyzing the existing HDR-BT literature at home and abroad,the authors review the safety and efficacy of HDR-BT in the treatment of NSCLC as well as its similarities and differences with other local therapeutic modalities such as stereotactic body radiation therapy,radio frequency ablation and 125I seed implantation by analyzing the existing relevant literature on HDR-BT at home and abroad.

  • This article has no references!
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn
Baidu
map